2017

  •  

    July 12, 2017 | Rapid, Near-patient Genomic Tests for Infectious Disease set to Revolutionize Antibiotic Prescribing and Patient Care

    Rapid, Near-patient Genomic Tests for Infectious Disease set to Revolutionize Antibiotic Prescribing and Patient Care

     

    DNAe CBO, Nick McCooke provides update in a presentation at Molecular Diagnostics World Summit 2017, 12 July, London

     

     

    London, UK and Carlsbad, CA, USA – 12 July 2017 - DNA Electronics (‘DNAe’), the inventor of semiconductor DNA sequencing technology and developer of a new, revolutionary sample-to-result diagnostic platform to rapidly determine the causative agent of infectious diseases, provided an update on its LiDia™ test for serious bloodstream infections (BSI), a condition which can lead to the potentially life-threatening complication of sepsis if not diagnosed and treated quickly. The test is on track for commercial launch in 2018.

     

    “Sequencing-related technologies have moved on rapidly from their use as research tools, with improvements now enabling real-life application in clinical settings. Bringing genomics and DNA sequencing closer to the patient will be transformative to the way that patients are treated, arming doctors with the information they need to make an informed decision when prescribing drugs. This not only leads to better outcomes for patients, but will help to curb the increase in antimicrobial resistance by fundamentally changing the way antibiotics are prescribed. Our LiDia BSI test for bloodstream infection is one of the first examples of a near-to-patient test that will enable swift treatment with the right antimicrobial drug.” said Nick McCooke, DNAe Group’s Chief Business Officer, during a presentation today at the Molecular Diagnostics World Summit 20171.

     

    DNAe’s pioneering work in bringing DNA sequencing into the clinical setting, is an example of where the UK has the potential to lead the way in genomics – as highlighted last week by Prof Dame Sally Davies, UK’s Chief Medical Officer in her report Generation Genome2.

     

    During his career, Mr McCooke led the British company that pioneered next-generation-sequencing (NGS) in the early 2000s, which has been fundamental in enabling the genomics revolution. He is now CBO at DNAe, which is commercialising semi-conductor sequencing. It is poised to lead the next step-change in DNA sequencing, bringing DNA sequencing into the near-to-patient clinical setting, by enabling the whole process of a DNA-based diagnostic test to be miniaturized and fully contained with clinically actionable results in just a few hours.

     

    DNAe's LiDia test for BSI overcomes many of the challenges currently associated with implementing near-to-patient genomic analysis as a routine diagnostic approach. It can be performed by non-specialists, enabling 24/7 use in healthcare settings such as hospitals. Results can be used to inform treatment decisions directly, without the need for any 'wet' microbiology labs or any additional analysis. The blood sample is fully contained in a sealed, disposable cartridge to avoid potential for contamination.

     

    In the UK, sepsis results in 44,000 deaths every year, more than bowel, breast and prostate cancer combined. Because treatment in the early stages of sepsis is so crucial to outcome and mortality rate, there is an urgent need for new, rapid diagnostics.

     

    In September 2016, the Biomedical Advanced Research and Development Authority (BARDA), a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to further develop LiDia™ for rapid diagnosis in two applications; antimicrobial resistant infections and influenza.  DNAe’s is the first NGS platform supported by BARDA, marking its game-changing potential in the diagnosis and treatment of infectious diseases.

     

    Lord O’Neill in his final report and recommendations on combatting antibiotic resistance, published in May 2016, highlighted the need for faster more accurate diagnostics in tackling this global threat saying “Most casual, and some very informed, observers automatically think the main part of the problem is getting new drugs. At least as big, if not bigger, is reducing the demand side, of which state-of-the-art diagnostics is front and center.”3

     

    1. Mr McCooke's presentation, ‘Rapid, User-Friendly, Sample-to-Result Diagnostic Sequencing’. For more information on Molecular Diagnostics World Summit 2017, please visit: http://www.moleculardiagnostics.co.uk.

     

    2. 2016 Annual Report: Generation Genome https://www.gov.uk/government/publications/chief-medical-officer-annual-report-2016-generation-genome

     

    3. Review on AMR: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf

     

     

     

    —Ends—

     

    About DNAe – www.dnae.com

    DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia™, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.’s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

     

    Contact Details

    DNAe

     

    Dr Steve Allen, Chief Executive Officer, DNAe Group

    Tel: +44 (0)20 7036 2100

     

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Alex Bannister / Deborah Bell

    Email: DNAe@instinctif.com

     

     

     

  •  

    March 18, 2017 | DNAe’s Semiconductor DNA Analysis Technology Featured in Nature’s Scientific Reports’ Top 100 Most Read Papers of 2016

    DNAe’s Semiconductor DNA Analysis Technology Featured in

    Nature’s Scientific Reports’ Top 100 Most Read Papers of 2016

     

     

    London, UK and Carlsbad, CA, USA – 18 May 2017  - DNA Electronics (‘DNAe’), the inventor of semiconductor DNA sequencing technology and developer of a new, revolutionary blood-to-result test for bloodstream infections, announces that an article on research utilizing the Company’s patented semiconductor DNA analysis technology has achieved recognition as one of the top 100 read articles for 2016 in Scientific Reports, a peer reviewed journal from the publishers of Nature.

     

    Research carried out by scientists at Imperial College, London (within the Division of Infectious Diseases and the Department of Bioengineering) and supported by DNAe, uses a novel approach for detecting the amount of virus present in the blood of HIV patients. If successfully developed into a test, it could in the future enable HIV patients to monitor their response to treatment, and provide an early alert to the patients and their doctors to the development of drug-resistance.

     

    The article, entitled ‘Novel pH sensing semiconductor for point-of-care detection of HIV-1 viremia’ was published on 10th November 20161. In November and December, the paper received 8,628 views, placing it within the top 100 most read of more than 20,000 articles published in Scientific Reports last year.

     

    The research involved analysis of 991 clinical samples, showing the method using DNAe’s technology had a high level of sensitivity (95%) and an average time to result of 20.8 minutes. Currently marketed tests take three or more days to detect the amount of HIV virus present in the blood, providing a strong indication of the very rapid performance of the underlying semiconductor DNA analysis technology, Genalysis®. This is a potential new application of Genalysis®, already being developed by DNAe for the diagnosis of serious bloodstream infections leading to sepsis, antimicrobial resistant infections and influenza2.

     

    Earlier this year, DNAe expanded its US operations and appointed four members to a newly formed Clinical Advisory Board in preparation for the launch of its first product, the LiDia™ Bloodstream Infection (BSI) Test. The test is being commercialized to address the urgent unmet need for a diagnostic capable of diagnosing the microbial cause of bloodstream infection leading to sepsis quickly and accurately. Responsible for over 200,000 deaths per annum in the US3, and 44,000 in the UK4, sepsis claims more lives than bowel, breast and prostate cancer combined4. Rapid diagnosis and treatment with the correct antibiotic can significantly reduce mortality rates. Unlike current blood culture based diagnostics which can take two to six days, the LiDia™ test for bloodstream infection will offer a ‘blood-to-result’ readout in just a few hours.

     

    Following its test for bloodstream infections, DNAe plans to expand the range of diagnostic tests available on the LiDia™ platform to include other disease areas where rapid diagnosis is a key factor in success of treatment.

     

    DNAe’s Founder and Executive Chairman, and Regius Professor at Imperial College London (Department of EEE) Professor Chris Toumazou (FRS, FREng, FMedSci) commented: “It is a great achievement for the whole team at Imperial and DNAe to have the article placed in Scientific Reports’ top 100 read list for 2016, and is a demonstration of the power and utility of DNAe’s technology. At DNAe, our focus is on applying our semiconductor sequencing and other technologies to address significant global threats to health, where treatment is time-critical and needs to be right first time.”

     

    Dr Steve Allen, CEO of DNAe Group Holdings commented: “The popularity of this article is a fantastic recognition for the team at Imperial, supported by our scientists, and is testament to the importance of the work they’re doing. This is a further example of the breadth of application of DNAe’s technology. We wish the Imperial team every success as they develop their research further.

    —Ends—

     

    References

    1. A copy of the research paper can be viewed here: https://www.nature.com/articles/srep36000
    2. In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza
    3. World Sepsis Day factsheet, Global Sepsis Alliance: http://www.world-sepsis-day.org/CONTENTPIC/2015_WSD_FactSheet_long_English.pdf
    4. UK Sepsis Trust: http://sepsistrust.org/

     

    Contact Details

    DNAE

     Dr Steve Allen, Chief Executive Officer, DNAe Group

    Tel: +44 (0)20 7036 2100

    Victor Esch, President and Chief Executive Officer, DNA Electronics Inc.

    Tel: +1 (760) 444-9410

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Deborah Bell / Alex Bannister

    Email: DNAe@instinctif.com

  •  

    March 6, 2017 | DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board

    DNAe Appoints International Infectious Disease Experts to its Newly Formed Clinical Advisory Board

     

    Founding CAB members are Professor Paul Dark, Professor Angela Caliendo,

    Professor Stephan Harbarth and Professor Romney Humphries

     

     

    London, UK and Carlsbad, CA, USA – 6 March 2017 – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the formation of its clinical advisory board (CAB). The CAB, with founding members Professor Paul Dark, Professor Angela Caliendo, Professor Stephan Harbarth and Professor Romney Humphries, brings together US and European experts to provide strategic guidance for the clinical development of DNAe’s diagnostic platform, LiDia™, and its accompanying range of tests for different clinical applications.

     

    “As we continue the commercialization of our technology and prepare for the launch of our first product, the LiDia™ Bloodstream Infection (BSI) Test, it is important that we work closely with experts to ensure that our products are aligned with hospital practice and best serve the medical need” said Dr Steve Allen, CEO of DNAe Group Holdings.

     

    Regius Professor Chris Toumazou, FRS, FREng, FMedSci, Founder and Executive Chairman of DNAe Group Holdings added: “The members of our new Clinical Advisory Board are each highly esteemed in their respective fields. They bring a range of expertise and clinical specialisms including clinical microbiology, sepsis, point-of-care diagnostics, critical care and hospital epidemiology, providing a perfect fit to our work in developing fast and powerful genomic tests for infectious diseases. We welcome their critical contribution to our product development and are confident they will contribute positively to our mission to bring cutting edge near-patient technology to the early diagnosis and monitoring of life threatening diseases.”

     

    The board is formed of the following distinguished academic clinicians:

     

    Professor Paul Dark, BSc, MD, PhD, FRCS, FRCEM, FFICM

     

    Professor Dark is Chair of Critical Care Medicine at the University of Manchester, UK, where he is responsible for developing postgraduate learning in research and innovation in acute healthcare. He is a senior clinical academic at the University, carrying out his duties as an NHS consultant in Critical Care Medicine at the Salford Royal NHS Foundation Trust. He is also a National Research Lead in Critical Care for the National Institute of Health Research (NIHR) and Visiting Professor at King’s College London. He leads a program of work funded by the NIHR, developing and assessing the diagnostic utility of emerging molecular technologies in the setting of sterile tissue injury and severe infection - focused on matrices in blood and breath. He has also led a program funded by Innovate UK, developing novel technologies aimed at rapid point-of-care infection/sepsis diagnosis. He advises NICE on diagnostic technology appraisals in sepsis and leads multi-center pragmatic clinical trials aimed at developing an improved evidence base for the management sepsis.

     

    Professor Angela Caliendo, MD, PhD, FIDSA

     

    Dr Caliendo is Professor, Executive Vice Chair of the Department of Medicine, and Director of the Division of General Internal Medicine at the Warren Alpert Medical School of Brown University, USA. She is an Editor for the Journal of Clinical Microbiology, Chair of the Microbiology Medical Devices Panel for the FDA and was Chair of the Diagnostics Task Force for the Infectious Diseases Society of America and is currently on the Board of Directors for the Infectious Diseases Society of America.  Dr. Caliendo’s research has focused on the development of molecular diagnostic tests for the detection and quantification of infectious diseases and assessment of their clinical utility.

     

    Professor Stephan Harbarth, MD, MS

     

    Dr Stephan Harbarth is Associate Professor the University of Geneva, Switzerland and Senior Consultant at Geneva University Hospitals. His group is currently conducting several clinical and epidemiological studies to evaluate key questions related to the control of the acquisition, transmission and infection by multidrug-resistant microorganisms. It is also participating in several ongoing large-scale EU-funded studies to address this public health threat and collaborating closely with the Genomics Research Laboratory at HUG (University of Geneva Hospitals), based on a productive translational research platform.

     

    Professor Romney Humphries, PhD, D(ABMM), M(ASCP)CM

     

    Dr Humphries is an Assistant Professor in the Department of Pathology and Laboratory Medicine in the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), USA. She is the Section Chief for Clinical Microbiology at UCLA Health and Chief Quality Officer for the Department of Pathology & Laboratory Medicine. Dr Humphries’ research focus is the detection and characterization of emerging antimicrobial resistance in bacteria, and the development of next generation diagnostic technologies. She is a member of the Clinical and Laboratory Standards Institute (CLSI) Antimicrobial Susceptibility Testing (AST) Subcommittee and Microbiology Resource Committee for the College of American Pathologists.

     

    —Ends—

     

    About DNAe – www.dnae.com

    DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing LiDia™, its sample-to-result genomic analysis platform, combining DNA Electronics Inc.’s Pathogen Capture System with its own portfolio of semiconductor-based genomic technologies, trademarked Genalysis®. The LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

     

    A private company, with bases in London, UK and Carlsbad, CA, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

     

     

    Contact Details

     

    DNAe

    Tel: +44 (0)20 7036 2100

     

    Dr Steve Allen, Chief Executive Officer

    Victor Esch, President and Chief Executive Officer, DNA Electronics Inc.

     

     

    Instinctif Partners (media relations)

    Tel: +44 (0)20 7457 2020

    Sue Charles / Alex Bannister / Deborah Bell

    Email: DNAe@instinctif.com

     

  •  

    Feb 22, 2017 | DNAe announces opening of US facility, expansion of operations and launches product brand as it prepares for commercialization

    DNAe announces opening of US facility, expansion of operations and launches  product brand as it prepares for commercialization

     

    • New California-based clinical diagnostic development and manufacturing facility opened

    • Diagnostic platform named as LiDia™

     

    London, UK and Carlsbad, CA, USA – 22 February 2017 – DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary blood-to-result test for bloodstream infections, announces the opening of its new US facility in preparation for commercializing its first product. DNAe also announces its new brand identity.

     

    Expansion of US operations

     

    Located in Carlsbad, California, DNAe’s new site expands its operations in the US and provides a specialized development and manufacturing base for its first product under the LiDia™ brand. The facility was officially opened by the Mayor of Carlsbad, Matt Hall and Councilman Michael Schumacher with a ribbon-cutting ceremony on 21st February 2017.

     

    Housing 15,000 square feet of laboratories including specialized cleanrooms and 9,000 square feet of office space, the Carlsbad site currently employs 38 people following relocation from the Company’s previous facility in Albuquerque, NM, with recruitment still ongoing.

     

    An area recognized globally as a hub for life sciences and technology, Carlsbad is an ideal location for DNAe as it grows its team and positions itself for commercialization. The Carlsbad facility will play a key role in integrating DNAe’s key technologies, namely high sensitivity sample processing and rapid DNA analysis.

     

    The Carlsbad site provides DNAe with the capacity to complete final development and begin commercial manufacture of its first test for bloodstream infections.

     

    Victor Esch, President and Chief Executive Officer, DNA Electronics Inc., based at the new Carlsbad facility said: “As we prepare to begin manufacturing our lead product, our new facility in Carlsbad enables us to tap into a wide pool of local talent and world class industry partners to support the next phase in our development. With these new facilities, and our strong and growing team, we are in an excellent position to make a game-changing impact in the infectious disease diagnostics space. Our first products will specifically address the huge global need for rapid diagnostics for sepsis.”

     

    Matt Hall, Mayor of Carlsbad commented, “Carlsbad is home to an active scientific community and we welcome DNAe, and the opportunities and skills it brings to the area.”

     

    Diagnostic platform name announced as LiDia™

     

    DNAe’s diagnostic platform will be named LiDia™. Based on DNAe’s Genalysis® DNA analysis technology, LiDia™ uses a combination of novel approaches, including ultra-sensitive sample preparation and semiconductor-based DNA analysis all within a single cartridge. The first LiDia™ test will be for bloodstream infection offering a broad test panel, capable of identifying the most critical suspected pathogens associated with bloodstream infections, as well as key antibiotic resistance markers.

     

    Referred to as a ‘national epidemic’ in the US, the human cost of sepsis is enormous: there are over 1 million cases in the US each year, and 28-50% of people with severe sepsis will die. A key factor is the speed at which a patient receives the appropriate antibiotics, with the chance of mortality increasing 8% every hour that a patient in septic shock does not receive the correct antibiotic for treating the causative organism.

     

    The LiDia™ test for bloodstream infection operates directly from blood, delivering a clinically-relevant report for the physician. Unlike current blood culture based diagnostics which can take two to six days, LiDia™ will offer a ‘blood-to-result’ readout in just a few hours.

     

    The introduction of the platform name is accompanied by a new website and brand identity for DNAe. The new website can be accessed at www.dnae.com.

     

    Dr Steve Allen, CEO of DNAe Group commented, “The opening of our Carlsbad facility lays the foundation for the next phase of our story, as we commercialize our technology toward market introduction of LiDia™. We are excited to be able to deliver on the extensive research and testing that has propelled us from a spin-out of Imperial College London to a company focused on improving clinical practice and patients’ lives through near-to-patient, blood-to-result rapid diagnostics.”

     

    —Ends—

     

    About DNAe – www.dnae.com

    DNAe is commercializing its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.’s Pathogen Capture System with its own Genalysis® semiconductor DNA sequencing technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. Its LiDia™ range of tests will enable DNA analysis directly on a microchip, providing rapid and accurate results from a user-friendly system. LiDia™ can operate in a variety of hospital environments close to the point of need with flexible levels of throughput to match a wide range of clinical demands. LiDia™ launches with the LiDia™ Bloodstream Infection (BSI) test, a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis.

     

    A private company, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

    Contact Details

     

    DNAe

    Tel: +44 (0)20 7036 2100

     

    Dr Steve Allen, Chief Executive Officer

    Victor Esch, President and Chief Executive Officer, DNA Electronics Inc.

     

     

    Instinctif Partners (media relations)

    Tel: +44 (0)20 7457 2020

    Sue Charles / Alex Bannister / Deborah Bell

    Email: DNAe@instinctif.com

     

  • 2016

  •  

    December 2, 2016 | DNAe Congratulates Executive Chairman Professor Chris Toumazou on Elektra European Electronics Industry Lifetime Achievement Award

     

    DNAe Congratulates Executive Chairman Professor Chris Toumazou on Elektra European Electronics Industry Lifetime Achievement Award

     

    Award recognises Professor Toumazou’s dedication to saving and improving lives through leading-edge innovations including semiconductor-based genomic technology

     

    London, UK and Carlsbad, CA – 2 December 2016 – DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for bloodstream infections, congratulates its founder and Executive Chairman Regius Professor Chris Toumazou (FRS, FREng, FIEEE, FIET, FRSM, FCGI, CEng, DEng, PhD) on receipt of the Lifetime Achievement Award which was presented at the 2016 Elektra European Electronics Industry Awards ceremony in London last night.

     

    Presented by electronics industry magazine Electronics Weekly, the award recognises Professor Toumazou’s pioneering career founded on his visionary application of electronic engineering to solve complex biological problems.  His achievements have included the invention and roll-out of several life-changing products based on semiconductor technology, such as miniature cochlear implants and an artificial Pancreas.

     

    Professor Toumazou’s invention of semiconductor genomic analysis has revolutionised next generation sequencing in laboratories around the world. DNAe was founded to develop this Genalysis® technology for use in rapid diagnostics with its first product being a ground-breaking test for serious blood infections leading to sepsis, an area of huge unmet medical need.

     

    At launch in 2018, the test will apply the powerful diagnostic capability into a rapid, user-friendly format. Unlike existing approaches, the platform operates directly from blood, without the need for a blood-culture step and dramatically reduces the wait for results, a key advantage when even an hour’s delay in treatment can significantly increase mortality rates.

     

    The technology is set to transform how patients with serious bloodstream infections are treated by not only enabling the rapid matching of the right drug to a patient, but also supporting the fight against antimicrobial resistance by enabling the clinician to prescribe the right antibiotic first time.

     

    Commenting on the award, Professor Toumazou said: “It is an honour to receive this Lifetime Achievement Award and such recognition from the electronics community. DNAe embodies the values that have driven my career; identifying and applying a novel technology to tackle areas of medical need, where its benefits can sometimes be the differentiating factor between life and death. I have always wanted to apply my invention of semiconductor-sequencing in a domain where rapid results and ease of use are important, and in the medical sector, diagnosis of infectious diseases like sepsis is a perfect application. It is fantastic to receive a Lifetime Achievement Award, but with so many other possible applications for this technology, I’m not done yet!”

     

    Dr Steve Allen, CEO of DNAe said, “The potential for Chris’ inventions is significant and he has already made a huge positive impact on many thousands of patients. At DNAe we are working to realise the potential of semiconductor-based genomic technology to revolutionise diagnosis of conditions such as sepsis, pandemic influenza and antimicrobial resistance, demonstrating its versatility and performance, and hopefully saving lives as a result.”

     

    In September 2016, DNAe secured a $51.9m contract from the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to develop Genalysis® for rapid diagnosis in a further two key applications; antimicrobial resistant infections and influenza. It is the first next generation sequencing platform (NGS) platform supported by BARDA.

     

    Professor Toumazou and his invention of semiconductor-based next-generation DNA sequencing was also recognised by the European Patent Office’s 2014 European Inventor Award for Research, the Institution of Engineering and Technology’s highest accolade, the Faraday Medal, and the Royal Society’s Gabor Medal in 2013.

     

    —Ends—

     

     

    About DNA Electronics – www.dnae.com

     

    DNAe is commercialising its pioneering semiconductor DNA analysis technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling early administration of appropriate treatment.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics, Inc.), a developer of a novel and highly sensitive system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.’s Pathogen Capture System with its own Genalysis® semiconductor DNA analysis technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe’s first product will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis. In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

     

    A private company, with operations in London, UK, and Carlsbad, CA and Washington, DC, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

    About Professor Professor Chris Toumazou, FRS, FREng, FMEDSci, FIET, FIEEE, FCGI, FRSM, DEng, PhD, BSc

    Professor Toumazou’s research is dedicated to saving and improving lives through the invention of revolutionary, innovative and disruptive technologies, including the creation of a leading edge medical research institute as well as four spin-out ventures to commercialise his ground-breaking inventions.

     

    Chris is London’s first Regius Professor of Engineering, at Imperial College London where he holds a Chair in Biomedical Circuits in the Department of Electrical and Electronic Engineering. He is also Director of the Centre for Bio-Inspired Technology, Founder and Chief Scientist of the Institute of Biomedical Engineering, and Executive Chairman of DNAe. DNAe is developing rapid diagnostics for life-threatening infectious diseases, based on Chris’ semiconductor DNA sequencing technology.  In recognition of this invention he won the 2014 European Inventor Award from the European Patent Office, the Institute of Engineering and Technology’s highest accolade, the Faraday Medal and the IEEE Field Medal for Bio-Engineering, both in 2015. In 2013, he was awarded the Royal Society Gabor Medal.

     

    Contact Details

     

    DNA Electronics Ltd Tel: +44 (0)20 7036 2100

    Professor Chris Toumazou, Founder

    Dr Steve Allen, Chief Executive Officer

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister Email: DNAe@instinctif.com

  •  

    Nov 9, 2016 | DNAe to Present New Data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at AMP 2016

    DNAe to Present New Data on G-BSI Blood-to-Result Test for Rapid Identification of Bloodstream Infections at AMP 2016

     

     

    London, UK and Carlsbad, CA, USA – 9 November 2016  DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology, announces that Vice President, Product Management, Dr Meghan Norvell, will present new data on the rapid detection of bloodstream infections directly from whole human blood samples at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, in Charlotte, NC.

     

    Dr Steve Allen, CEO DNAe Group Holdings said: “AMP 2016 is a greatly respected conference and an ideal place for us to present data on our complete end-to-end workflow for the first time. This includes bacterial, fungal and antibiotic resistance gene targets at low limits of detection. Our Genalysis® platform for serious bloodstream infections (G-BSI) detects and identifies pathogens directly from whole human blood”.

     

    “Referred to as a ‘national epidemic’ in the US, the human cost of sepsis is enormous: there are over 1 million cases in the US each year, and 28-50% of people with severe sepsis will die.  A key factor is the speed at which a patient receives the appropriate antibiotics, with the chance of mortality increasing 7.6% every hour that a patient in septic shock does not receive the correct treatment. Compared to current tests, which can take up to three days, G-BSI will enable a turnaround time of just a few hours, addressing a huge and urgent unmet need.”

     

    Details of Poster Presentation:

     

    Title: ‘Rapid, Sensitive Detection of Clinical Bloodstream Infections Directly from Whole Human Blood’

    Location: Infectious Diseases poster session, Exhibit Hall

    Poster number: ID67

    Presenter: Dr Meghan Norvell, with Senior Scientist, Dr Cathal McElgunn

    Time: Saturday 12 November, 9:45 am - 10:45 am

     

    DNAe’s G-BSI test uses a combination of novel technologies, including ultra-sensitive sample preparation to remove the time-consuming blood culture step, and semiconductor-based real time PCR for rapid pathogen detection. This allows the test to identify the most prevalent causes of bloodstream infections and key antibiotic resistance markers within just a few hours of sample presentation. The test can be performed by non-specialist laboratory personnel and simply requires a standard 10 mL blood collection tube containing the sample to be slotted into a cartridge, which is then inserted into the instrument.

     

    Regius Professor Chris Toumazou, Founder and Executive Chairman, DNAe Group Holdings, said: “This data will demonstrate both the great progress being made in the development of our G-BSI test, and the suitability of DNAe’s semiconductor-based DNA analysis technology for the diagnosis of sepsis, where time to result is a critical factor in reducing mortality. This is a testament to the platform, the team and the strategy we have in place to revolutionise how serious bloodstream infections are diagnosed and treated.”

     

    The AMP 2016 Annual Meeting takes place from 10-12 October. To meet Dr Meghan Norvell or Dr Cathal McElgunn at the event, please email contact@dnae.com.

     

    —Ends—

     

     

    About DNA Electronics – www.dnae.com

    DNAe is commercialising its pioneering semiconductor DNA analysis technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling early administration of appropriate treatment.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics, Inc.), a developer of a novel and highly sensitive system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.’s Pathogen Capture System with its own Genalysis® semiconductor DNA analysis technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe’s first product will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis. In October 2016, the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) awarded DNAe a contract worth up to $51.9 million to develop Genalysis® for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

     

    A private company, with operations in London, UK, and Carlsbad, CA and Washington, DC, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

    Contact Details

     

    Professor Chris Toumazou, Chairman Tel: +44 (0)20 7036 2100

    Dr Steve Allen, Chief Executive Officer (London, UK)

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister  Email: DNAe@instinctif.com

     

  •  

    Sept 30 2016 | BARDA Awards $51.9 Million Contract to DNAe to Develop Semiconductor DNA Sequencing Platform for Rapid Diagnosis of Antimicrobial Resistant Infections and Influenza

    BARDA Awards $51.9 Million Contract to DNAe to Develop Semiconductor DNA Sequencing Platform for Rapid Diagnosis of Antimicrobial Resistant Infections and Influenza

     

    • First next-generation sequencing platform to receive funding from BARDA

    • Up to $51.9 million, contract to support testing and FDA clearance of DNAe’s sequencing platform for a series of applications

    • Initial focus to address two of the most significant threats to global health, antimicrobial resistance and influenza

     

    London, UK and Carlsbad, CA, USA – 30 September 2016  DNA Electronics (‘DNAe’), the inventors of semiconductor-based next-generation DNA sequencing (NGS) technology and developers of a revolutionary blood-to-result test for bloodstream infections, announces that the Biomedical Advanced Research and Development Authority (BARDA) a division of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) has awarded the Company a contract worth up to $51.9 million to develop its sequencing platform for rapid diagnosis in two key applications; antimicrobial resistant infections and influenza.

     

    Genomic information derived from DNA sequencing is transforming many areas of medicine. This is the first NGS platform supported by BARDA, with game-changing potential in the diagnosis and treatment of infectious diseases.

     

    The Centers for Disease Control and Prevention (CDC) have estimated that more than 2 million people per year in the U.S. suffer antimicrobial resistant infections resulting in 23,000 deaths. The CDC also predicts that a flu pandemic could result in between 89,000 and 207,000 deaths in the U.S. and could cost the economy $71.3-166.5 billion.

     

    The contract for the project entitled PISCES (Pathogen Identification from Specimen, via Capture Extraction and Sequencing) will enable DNAe to complete the development and validation of its ground-breaking Genalysis® platform and support a series of applications to the U.S. Food and Drug Administration for marketing clearance.

     

    The Genalysis® platform will combine the ability to sequence the DNA of the infectious organism, in a sealed microchip based system, direct from clinical specimen, with analysis that enables actionable identification of the disease agent within a few hours, a key requirement in the effective treatment of infectious diseases.

     

    DNAe’s first product will be a rapid blood-to-result diagnostic system to meet an unmet need in the treatment of serious bloodstream infections leading to sepsis. Sepsis is an area of very high unmet medical need, responsible for over 200,00 deaths per annum in the US, more than prostate cancer, breast cancer and AIDS combined1. In late stage development and testing, the new system is set for commercial launch in 2018.

     

    In 2014, BARDA awarded a $21.5 million, contract to DNAe’s US operation (then called nanoMR, Inc.) to develop an automated sample preparation system that could reduce the time needed to test for bloodstream infections and biothreat agents such as anthrax from days to hours. DNAe acquired nanoMR in January 2015 to complete the workflow of its sample-to-result solution by combining nanoMR’s novel Pathogen Capture System, which extracts and concentrates pathogens, such as bacteria or fungi directly from a raw blood sample, with its Genalysis® technology.

     

    Sam Reed, President, U.S. Office, DNAe, based in Washington DC, and who is leading DNAe’s sequencing program commented: “Our platform is truly revolutionary as it brings a powerful sequencing-based diagnostic capability into a rapid, user-friendly format. Importantly the platform can be operated by users who are not specially-trained in sequencing, enabling it to be used in a wide range of near-to-patient clinical environments where sequencing has not been possible before. Unlike existing sequencing devices, the platform operates ‘push button’ directly from raw clinical specimens such as blood or swabs, delivering a clinically-relevant report for the physician.”

     

    Bloodstream infections afflict over 1 million patients per year in the US alone, making it the single most expensive disease in terms of total healthcare expenditure2.  DNAe’s Genalysis® platform will revolutionize care by very rapidly identifying the causative pathogens and their antibiotic resistance profile from a wide range of potential causes. This has the potential to drive reduced mortality, reduced length of stay in critical care, reduced healthcare expenditure, and improved management of antibiotics. In influenza testing, the platform has the potential to ultimately identify the strain subtype and antiviral resistance markers, guiding antiviral usage in critical patients or for management of patients during a pandemic.

     

    Dr Steve Allen, CEO DNAe Group Holdings said: “DNA sequencing-based tests that can rapidly provide accurate diagnostic information on infectious diseases will be a game-changer in terms of how clinicians treat infectious diseases in the future. It will enable the choice of treatment to be highly specific and tailored to the causative pathogens. Antimicrobial resistance and the threat of an influenza pandemic are two of the most critical threats to human life, and areas of huge unmet need. The support and cooperation of the U.S. Government will be instrumental in our mission to provide rapid diagnostics to support healthcare professionals, enabling a more effective public health response to these crises.”

     

    Semiconductor-based DNA sequencing was invented by DNAe’s Founder, Executive Chairman, and Regius Professor at Imperial College London (Department of EEE), Professor Chris Toumazou and his group at Imperial. A highly acclaimed serial entrepreneur, this invention has earned him the UK Institution of Engineering and Technology (IET)’s highest honour, the Faraday Medal and the European Patent Office’s prestigious Inventor of the Year Award for Research in 2014, and the Gabor Medal of the Royal Society in 2013. DNAe owns and applies his patented technology to create rapid diagnostics that address critical unmet needs in healthcare applications. The semiconductor sequencing technology is licensed to Thermo-Fisher for research use.

     

    Professor Toumazou, DNAe said: “This collaboration demonstrates the suitability of DNAe’s NGS-based platform to address a range of clinical needs, demonstrated by the applications in antimicrobial resistance and influenza testing, where there is a very high unmet need.”

     

     

    —Ends—

     

     

    About DNA Electronics – www.dnae.com

    DNAe is commercialising its pioneering semiconductor DNA analysis technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.’s Pathogen Capture System with its own Genalysis® semiconductor DNA analysis technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe’s first product, will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis.

     

    A private company, with operations in London, UK, and Carlsbad, CA and Washington DC, USA, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

    References

     

    1. World Sepsis Day factsheet, Global Sepsis Alliance: http://www.world-sepsis-day.org/CONTENTPIC/2015_WSD_FactSheet_long_English.pdf

    2. Celeste M. Torio, Ph.D., M.P.H. and Roxanne M. Andrews, Ph.D.: National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.pdf

     

     

     

    Contact Details

     

    Dr Steve Allen, Chief Executive Officer (London, UK)                           Tel: +44 (0)20 7036 2100

    Sam Reed, President, U.S. Office (Washington, USA)                            Tel:  +1 202 779 2640

     

     

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister  Email: DNAe@instinctif.com

     

  • 2015

  •  

    Dec 4, 2015 | DNAe Expands US Operations with Clinical Diagnostic Development and Manufacturing Site in San Diego

    DNAe Expands US Operations with Clinical Diagnostic Development and Manufacturing Site in San Diego

     

    Relocation from current site in Albuquerque will double headcount and ideally positions DNAe for the launch of its Genalysis® platform and bloodstream infection assays

     

     

    London, UK and Albuquerque, NM, USA – 4 December 2015 DNA Electronics (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for bloodstream infections, will expand and relocate its US operations from Albuquerque, NM to San Diego, CA. The move is expected to be completed by the end of 2016.

     

    Located in an area recognized globally as a hub for life sciences and technology, DNA Electronics Inc. will be ideally situated to grow its experienced team. The relocation to San Diego is essential as DNAe enters the final development and manufacturing stages for launch of its rapid point-of-need in vitro diagnostic (IVD) for bloodstream infections. The Company intends to expand capacity significantly, increasing its US-based headcount from 29 to over 50 and building a specialized clinical diagnostic manufacturing facility, clinical testing laboratories and a commercial team.

     

    DNA Electronics Inc. (previously nanoMR Inc.) was founded in 2006 as a spin-out of the University of New Mexico. The Company, which has developed novel Pathogen Capture System technology, was acquired by UK-based DNAe in January 2015. DNAe is integrating its Genalysis® semiconductor DNA sequencing technology with this Pathogen Capture System to develop an IVD for serious blood infections that lead to sepsis.

     

    Victor Esch, Chief Executive Officer, DNA Electronics Inc. said: “Albuquerque has been a fantastic place to build our innovation-led business and develop our technology over the past decade. As we transition into our next stage of development, building our operations towards the launch of our pioneering test for serious blood infections, San Diego offers us the opportunity to expand our workforce and exploit opportunities within the San Diego life sciences hub.

    “The new site will be close to our major development partners and suppliers, the clinical diagnostic expertise to grow our team further and great transport links which positions us ideally for forthcoming clinical trials and manufacturing. We are proud of our heritage and will be maintaining strong links with our partners in Albuquerque including with the University of New Mexico and TriCore Reference Laboratories.”

     

    Prof. Chris Toumazou, Executive Chairman, DNAe said: “We are making great progress in the development of our bloodstream infections test and, with our £25 million Citibank facility in place, we have the finances to enable us to invest in the staff, R&D and facilities needed as we progress rapidly towards the launch of our first test system in 2017.

     

    “The expansion of US operation is central to achieving this objective, and to bringing a much needed point-of-need test to the infectious disease management setting. We look forward to completing clinical development and to begin manufacturing on-site.”

     

    The increase in capacity will create skilled job opportunities in specialty manufacturing, clinical development, regulatory and commercial positions. All existing staff at the Albuquerque site have been offered roles in San Diego with most expected to relocate throughout 2016.

     

    —Ends—

     

     

    About DNA Electronics – www.dnae.com

    DNAe is commercialising its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.’s Pathogen Capture System with its own Genalysis® semiconductor DNA sequencing technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe’s first product, will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis.

     

    A private company, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

     

    Contact Details

     

    DNA Electronics Inc.      Tel: +1 505 924 6300

    Victor Esch, President and Chief Executive Officer

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister  Email: DNAe@instinctif.com

     

  •  

    Nov 2, 2015 | DNAe Secures £25 million ($38 million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections

     

    DNAe Secures £25 million ($38 million) Bank Facility to Fund Development of Pioneering Point-of-Need IVD for Serious Blood Infections

     

    London, UK and Albuquerque, USA – 2 November 2015 DNAe, the inventors of semiconductor DNA sequencing technology, have secured a bank facility of £25 million ($38 million) to fund the final development stages of DNAe Diagnostics’ revolutionary point-of-need test for serious blood infections. This will include clinical trials targeted for 2016 and product launch in 2017.

     

    The facility, with Citibank, follows an internal fundraising exercise that raised $24 million in January 2015 to fund DNAe’s acquisition of Albuquerque, USA-based nanoMR, Inc. (now DNA Electronics, Inc.).

     

    DNAe is applying its Genalysis® semiconductor DNA sequencing technology to develop a rapid in vitro diagnostic for serious blood infections that lead to sepsis. The test integrates DNA Electronics Inc.’s novel Pathogen Capture System technology with DNAe’s Genalysis® platform, to provide a complete blood-to-result diagnostic solution with actionable results in 2-3 hours. This is a major step forward from current approaches, which can take days, in an area where time-to-result is a critical factor.

     

    Prof. Chris Toumazou, Executive Chairman, DNAe said: “The development of our serious bloodstream infections test is progressing well. Following the acquisition and integration of nanoMR, Inc. earlier this year, we are in a great position to achieve our objective to launch our in vitro diagnostic system in 2017. Our semiconductor DNA semiconductor technology has the potential to revolutionise how patients with these life-threatening infections are treated and the bank facility demonstrates the confidence of the bank and of our shareholders in DNAe’s technology, team and strategy to achieve this.”

     

    —Ends—

     

     

    About DNA Electronics – www.dnae.com

    DNAe is commercialising its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    In January 2015 DNAe acquired nanoMR, Inc. (now DNA Electronics Inc.), a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample to result genomic analysis platform combining DNA Electronics Inc.’s Pathogen Capture System with its own Genalysis® semiconductor DNA sequencing technology. Built into a compact device for use at the point of need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease.

     

    DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. DNAe’s first product, will be a diagnostic test for bloodstream infections for use in the management and prevention of sepsis.

     

    A private company, DNAe has strong financial backing from its investors, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of cutting–edge life sciences companies.

     

     

    Contact Details

     

    DNA Electronics Ltd Tel: +44 (0)20 7036 2100

    Professor Chris Toumazou, Executive Chairman

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister Email: DNAe@instinctif.com

     

  •  

    May 27, 2015 | DNAe Chairman Professor Chris Toumazou Awarded IEEE Field Medal in Biomedical Engineering for Outstanding Contributions to Biomedical Circuit Technology

     

    DNAe Chairman Professor Chris Toumazou Awarded IEEE Field Medal in Biomedical Engineering for Outstanding Contributions to Biomedical Circuit Technology

     

    London, UK – 27 May 2015 DNA Electronics (‘DNAe’), the inventors of semiconductor DNA analysis technology and developers of a new, revolutionary point-of-need test for serious blood infections, congratulate its founder and Chairman Professor Chris Toumazou who accepted the Institute of Electrical and Electronics Engineers’ (IEEE) prestigious 2015 Field Medal in Biomedical Engineering last night. Professor Toumazou’s research is dedicated to saving and improving lives through the invention of revolutionary, innovative and disruptive technologies.

     

    The award was presented by IEEE President and CEO, Howard E. Michel at a ceremony during the 2015 International Symposium on Circuits and Systems (ISCAS) in Lisbon. It recognises Professor Toumazou’s contributions to biomedical circuit technology which includes the invention of semiconductor DNA analysis and its ability to revolutionise healthcare and save lives.

     

    Commenting on the award Professor Toumazou said: “My research is driven by an acute awareness of areas of unmet medical need, and in identifying how electronic inventions can help. The ability to reduce time to diagnosis in serious blood infections from days to just a few hours using our semiconductor DNA analysis platform can mean the difference between life and death for some patients. I am honoured that the IEEE has recognised my work. ”

     

    Semiconductor DNA analysis converts a natural biochemical reaction to an electrical signal. Unlike other DNA analysers, the technique does not require bulky optical systems to look at unnatural fluorescent dyes fixed to DNA molecules, and offers major benefits of rapidity, economy and compact DNA analysis. Since 2010, under license from DNAe, semiconductor DNA sequencing has been used in laboratories all over the world and forms the core of Thermo Fisher’s Ion Torrent™ bench-top DNA sequencer.

     

    Professor Toumazou’s invention of semiconductor DNA sequencing was recognised by the European Patent Organisation’s 2014 European Inventor Award for Research, the Institution of Engineering and Technology’s highest accolade, the Faraday Medal, and the Royal Society’s Gabor Medal in 2013.

     

    DNAe is developing semiconductor DNA analysis technology for use in a pioneering rapid test for serious blood infections leading to sepsis. The test will integrate novel sample preparation technology recently acquired via its acquisition of Albuquerque-based nanoMR Inc. to provide a complete blood-to-result diagnostic solution with actionable results in 2-3 hours. This is a major step forward from current approaches which can take days, in an area where time-to-result is a critical factor.

     

    Professor Toumazou’s other ‘medical microchip’ inventions include the world’s first totally implantable cochlear prosthetic for born-deaf children and the first wireless healthcare patch to monitor patients’ vital signs remotely, allowing them to be discharged from hospital.

     

    IEEE President and CEO, Howard E. Michel said: "Professor Toumazou is an engineer who has developed numerous medical devices that have revolutionised healthcare. The IEEE is the world's largest professional association dedicated to advancing technological innovation for the benefit of humanity and Professor Toumazou's work was a stand-out contender for the Biomedical Engineering Award in what was a very competitive field."

     

    —Ends—

     

     

     

    About DNA Electronics – www.dnae.com

    DNA Electronics Ltd (‘DNAe’) is commercialising its pioneering semiconductor DNA analysis technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    Through a non-exclusive license to Thermo Fisher, the performance of DNAe’s semiconductor DNA sequencing technology has been proven as the core of the Ion Torrent™ Next Generation Sequencing (NGS) system.

     

    In January 2015 DNAe acquired nanoMR Inc. a developer of a novel system for rapid isolation of rare cells in the bloodstream. DNAe is developing a complete sample-to-result genomic analysis platform combining nanoMR’s Pathogen Capture System with its own Genalysis® semiconductor DNA analysis technology. Built into a compact device for use at the point-of-need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease. DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The Company’s first test will be a diagnostic for blood stream infections for use in the management and prevention of sepsis.

     

    About Professor Professor Chris Toumazou, FRS, FREng, FMEDSci, FIET, FIEEE, FCGI, FRSM, DEng, PhD, BSc

    Professor Toumazou’s research is dedicated to saving and improving lives through the invention of revolutionary, innovative and disruptive technologies, including the creation of a leading edge medical research institute as well as spin-out ventures to commercialise his ground-breaking inventions namely DNA Electronics Ltd (DNAe), GENEU and Toumaz Group plc.

     

    Chris is London’s first Regius Professor of Engineering, at Imperial College London where he holds a Chair in Biomedical Circuits in the Department of Electrical and Electronic Engineering. He is also Director of the Centre for Bio-Inspired Technology, Founder and Chief Scientist of the Institute of Biomedical Engineering, and Chairman of DNAe. DNAe is developing point-of-need diagnostics for life-threatening infectious diseases, based on Chris’ semiconductor DNA sequencing technology.  In recognition of this invention he recently won the 2014 European Inventor Award from the European Patent Office, the Institute of Engineering and Technology’s highest accolade, the Faraday Medal and was awarded the Royal Society Gabor Medal 2013.

     

    Contact Details

     

    DNA Electronics Ltd Tel: +44 (0)20 7036 2100

    Professor Chris Toumazou, Chairman

    Dr Steve Allen, Chief Operating Officer

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister Email: DNAe@instinctif.com

     

  •  

    January 19, 2015 | DNAe Acquires nanoMR Inc. in a Strategic Move to Own Complete Workflow for Point-Of-Need NGS-Based Blood-To-Result Diagnostic

     

    DNAe Acquires nanoMR Inc. in a Strategic Move to Own Complete Workflow for Point-Of-Need NGS-Based Blood-To-Result Diagnostic

     

    Acquisition enables immediate presence in USA, a key market for bloodstream infection diagnosis

    and other applications

     

    London, UK and Albuquerque, NM, USA – 19 January  2015  - DNA Electronics Ltd (‘DNAe’), the inventors of semiconductor DNA sequencing technology and developers of a new, revolutionary point-of-need test for blood infections, has on 15 January 2015 completed the acquisition of the entire issued share capital of nanoMR Inc. (‘nanoMR’), an Albuquerque based developer of a novel system for rapid isolation of rare cells in the bloodstream for a total cash consideration of approximately $24 million by way of a merger under the laws of Delaware, USA.

     

    Integration of the two organisations is effective immediately, creating an 80+ strong team with facilities in the UK and the USA that will operate under the DNAe brand. The acquisition is a key strategic milestone for DNAe, enabling the Company to integrate nanoMR’s unique immunomagnetic Pathogen Capture System (PCS) with its own Genalysis® PCR and semiconductor-based DNA sequencing technology to create a complete blood-to-result solution.

     

    The PCS can target multiple rare cell types such as those contained in bacteria and fungi from bloodstream infections at levels of 1 cell/mL or lower in less than 30 minutes, making it the ideal sample preparation technology for DNAe’s rapid point-of-need diagnostic tests. DNAe’s proven semiconductor DNA sequencing technology is already licensed to Thermo Fisher and is the core of the Ion Torrent™ Next Generation Sequencing (NGS) systems as well as to Geneu, a company selling the world's first in-store DNA test for personalised skincare.

     

    DNAe is developing an integrated instrument and consumable cartridge that will deliver results directly from blood in 2-3 hours. Its first diagnostic product, a test for the rapid diagnosis of bloodstream infections, will identify pathogens in the blood as well as antimicrobial resistance genes. This will allow clinicians to treat patients with appropriate medication before the onset of sepsis, saving lives and reducing the time spent in hospital.

     

    Professor Chris Toumazou, Chairman and CEO of DNAe said: “The acquisition of the nanoMR technology and team underscores our commitment to developing a complete point-of-need solution for diagnosis of infectious diseases, particularly those that cause sepsis, where speed and DNA-specific information can make the difference between life and death. nanoMR brings a game-changing technology, a wealth of scientific expertise and the potential for exciting new applications to DNAe.”

     

    The combined company will continue to work on nanoMR contracts including the development of PCS and assays for potential infectious agents for the US Department of Health and Human Services Biomedical Advanced Research and Development Agency (BARDA) and will further invest in the development of PCS from its US facility. The UK-based operation will focus on developing Genalysis® technology as part of an integrated system.

     

    nanoMR’s CEO Victor Esch said: “By combining our PCS technology with the powerful molecular diagnostic technology developed by DNAe we are in a strong position to create a blood-to-result system with unmatched versatility and performance. DNAe is the perfect match for nanoMR and we look forward to a great future as part of the combined team.”

     

    DNAe is an ambitious company led by a highly experienced management team. It has strong financial backing, including major shareholder Genting Berhad, a Malaysian-based global investor with a growing portfolio of

    cutting–edge healthcare companies.

     

    Tan Sri Lim Kok Thay, CEO and Chairman of Genting Berhad said: “This is a major value-creating deal for DNAe. The development of these ground-breaking technologies to address the huge unmet medical need for rapid

    point-of-need testing for sepsis, as well as other applications, makes it a stand-out company that we are proud to support. We are convinced that the acquisition of the nanoMR technology and the drive and commitment of the management team to accelerate development towards commercialisation will make a major contribution to the improvement of patient care.”

     

    Outcome Capital acted as exclusive advisor to nanoMR in the transaction.

     

     

    —Ends—

     

    About DNAe – www.dnae.com

    DNA Electronics Ltd (‘DNAe’) is commercialising its pioneering semiconductor DNA sequencing technology for healthcare applications where rapid near-patient live diagnostics is needed to provide actionable information to clinicians, saving lives by enabling the right treatment at the right time.

     

    Through a non-exclusive license to Thermo Fisher, DNAe’s semiconductor sequencing technology is the core of the Ion Torrent™ Next Generation Sequencing (NGS) systems, proving its performance at the laboratory scale.

     

    DNAe’s Genalysis® system is a sample-to-result genomic analysis platform based on semiconductor sequencing.

    Built into a compact device for use at the point-of-need, the system will diagnose accurately and rapidly what infection a patient has, providing the clinician with actionable information to help select the appropriate antibiotics to treat the disease. DNAe’s initial focus is on infectious disease diagnostics, where speed and DNA-specific information can make the difference between life and death. The Company’s first test will be a diagnostic for blood stream infections for use in the management and prevention of sepsis.

     

    About nanoMR – www.nanomr.com

    Founded in 2007 by researchers  from the University of New Mexico, nanoMR is an early-stage life sciences company developing novel diagnostic systems for the rapid isolation of rare cell types, including bacterial and fungal  pathogens, directly from blood and other matrices.

     

    nanoMR’s products use an immunomagnetic capture process that can deliver either viable cells for phenotypic analysis, or extracted DNA for molecular analysis by different DNA-based platforms, including PCR, hybridization and DNA sequencing. The Company’s first product addresses the blood culture market, demonstrating identification of blood-borne infections in less than two hours, compared with days required for conventional blood-culture-based systems.

     

     

    —Ends—

     

    Contact Details

    DNA Electronics Ltd Tel: +44 (0)20 7036 2100

    Professor Chris Toumazou, Chief Executive Officer

    Dr Steve Allen, Chief Operating Officer

     

    Instinctif Partners (media relations) Tel: +44 (0)20 7457 2020

    Sue Charles / Jen Lewis / Alex Bannister Email:

    DNAe@instinctif.com

     

     

     

COMPANY DETAILS

 

Email: contact@dnae.com

Switchboard: +44 (0)20 7036 2100

Fax: +44 (0)20 7036 2144

Twitter: @dna_electronics

OFFICE  LOCATIONS

DNAe Group Holdings Ltd

Ugli Campus Block C

56 Wood Lane

London

W12 7SB

United Kingdom

 

Google map

DNA Electronics, Inc.

1891 Rutherford Road

Suite 100

Carlsbad, CA 92008

USA

+1 (760) 444-9410

 

Google map

KEEP IN TOUCH

© 2017 DNA Electronics    Privacy & Cookies | Terms of Use

Submitting Form...

The server encountered an error.

Thank you for joining our mailing list